Equity Research on Forest Laboratories Inc. and Endo Health

Equity Research on Forest Laboratories Inc. and Endo Health Solutions Inc. - Patent Expiries and New Releases Lead to Mixed Results for Drug Manufacturers  JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 07/30/12 --  www.StockCall.com offers free research on Forest Laboratories Inc. (NYSE: FRX) and Endo Health Solutions Inc. (NASDAQ: ENDP) from the Drug Manufacturers - Other industry. Access these reports by clicking on the links below or by copy and pasting those to your address bar.   www.StockCall.com/reports   The drug manufacturers industry, which features companies such as Forest Laboratories Inc. and Endo Health Solutions Inc. continues to be negatively impacted by patent expirations. Several major brand-name drugs have lost exclusivity as of late, and the results are appearing on company financials.   StockCall.com is an online platform where investors doing their due-diligence on the Drug Manufacturers - Other industry can have easy and free access to our analyst research and opinions on Forest Laboratories Inc. and Endo Health Solutions Inc. To see how companies in this industry have grown over the past years and how they are expected to perform in the future, please visit the link below.  www.StockCall.com  In the case of Forest Laboratories, the company recently reported that earnings from its fiscal 1st quarter came in at $55.3 million, down substantially from earnings of $258.1 million achieved during the same quarter last year. One reason for the decline was the loss of exclusivity for Lexapro. Endo Health has also been dealing with challenges stemming from losses of exclusivity. Register now to have free access to our report on Endo Health Solutions Inc., and to do so please click the link below.  www.StockCall.com/ENDP300712.pdf   In an attempt to improve sales and grow revenues, companies in the industry have been working hard on releasing new products. Forest Laboratories together with Almirall S.A. have recently had success in this regard, stating that the FDA has approved Tudorza(TM) Pressair(TM) for the treatment of Bronchospasm associated with chronic obstructive pulmonary disease. Investors and shareholders of Forest Laboratories Inc. can simply register for our complimentary reports by clicking on the link below.  www.StockCall.com/FRX300712.pdf   About StockCall.com   StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.   Contact Person: William T. Knight stockcall2010@gmail.com     
Press spacebar to pause and continue. Press esc to stop.